AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Fiercebiotech

Published November 10, 2026

Merck's MASH hopeful efinopegdutide wins in mid-stage study - Fierce Biotech

Read the full story at Fiercebiotech

Fierce Biotech at London Life Sciences Week. The Savoy, London. 17 Nov ... psychedelic for depression. Nov 9, 2026 10:30am. Related Content Image.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic biotech